![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Clinical Trials
Valneva Announces Positive Homologous Booster Data for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
Valneva SE, a specialty vaccine company, announced positive homologous booster data from the Phase 1/2 study, of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001....
Clinical Trials
CASI Pharmaceuticals And Bioinvent Announce CTA Approval For Clinical Study Of BI-1206 In NHL In China
CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that the China National Medical Products...
Clinical Trials
Clovers COVID-19 Vaccine Candidate Administered as Heterologous Booster in Investigator-Led Phase 2 Clinical Trial
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced that an investigator-led, Phase 2 trial initiated to...
Clinical Trials
Emmes Announces Completion of Third ACTT Clinical Trial for COVID-19
Emmes announced that it conducted the data and statistical analysis for the third iteration of the Adaptive COVID-19 Treatment Trial (ACTT-3), using its proprietary...
Clinical Trials
Ascelia Pharma presents study showing comparable efficacy of Orviglance lesion visualization and detection to Gadolinium
Ascelia Pharma AB is presenting a study in which Orviglance® (manganese chloride tetrahydrate, former working name Mangoral) was compared against a gadolinium-based contrast agent...
Clinical Trials
Single Dose of Regen-Cov Provides Long-Term Protection Against COVID-19
Single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4%...
Clinical Trials
Ferrer announces first patient enrollment of FNP122 in ADORE Phase III clinical trial for Amyotrophic Lateral Sclerosis treatment
Ferrer, an international pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has announced the next major milestone in its...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read